Metabolic Syndrome Worsens Pain Catastrophizing in Psoriatic Arthritis
Findings suggest MetS is linked to greater levels of pain catastrophizing in psoriatic arthritis, highlighting the need for multidisciplinary care.
Related Articles
Diabetes Dialogue: CATALYST Reveals High Prevalence of Hypercortisolism in T2D
In this episode, hosts explore the findings of the Catalyst trial on hypercortisolism and its impact on type 2 diabetes.
MASLD, MetALD Associated with Accelerated Brain Aging, Study Finds
Findings suggest the benefit of MASLD-focused anti-inflammatory interventions for promoting brain health and preventing accelerated brain aging.
Dietary Interventions, Resulting Weight Loss Improve Symptoms of Psoriatic Arthritis
These data suggest promise for dietary interventions and anti-obesity therapies such as incretin-based weight loss medicines for those with psoriatic arthritis (PsA).
Experiences with JAK Inhibitors Highlighted Among Black Patients with Alopecia Areata
These data were the conclusion of a case series highlighting the experiences and responses of African American patients with alopecia areata who utilize JAK inhibitors.
TEV ‘749 Survey Shows Many Nurses Prefer Intramuscular Injections, with Andrew Cutler, MD
Cutler told HCPLive it was surprising that a new survey on subcutaneous TEV- ‘749 revealed 50% and 45.5% of nurses and physicians, respectively, preferred intramuscular…
FDA Approves Upadacitinib, Expanding Treatment for Adults With Giant Cell Arteritis
Upadacitinib joins tocilizumab as the second therapy to be approved for treating GCA.
Turning the Tide: Early PCSK9 Intervention Post-ACS
Experts discuss actionable insights on leveraging early PCSK9 inhibitor intervention to help improve outcomes and prevent recurrent cardiovascular events in patients post ACS events.
Hepatology
HCPLive is a clinical news and information portal, offering physicians specialty and disease-specific resources, conference coverage, and interviews.
FDA Approves Upadacitinib, Expanding Treatment for Adults With Giant Cell Arteritis
Upadacitinib joins tocilizumab as the second therapy to be approved for treating GCA.
FDA Approves Pz-cel (Zevaskyn) Gene Therapy for RDEB
This FDA approval makes pz-cel the first single application therapy to receive FDA approval for recessive dystrophic epidermolysis bullosa.